Sign in
Back
ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?
Journal article   Open access  Peer reviewed

ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?

Ralf Landgraf
Cancer biology & therapy, Vol.10(6), pp.564-566
2010-09-15
DOI: https://doi.org/10.4161/cbt.10.6.12997
PMCID: PMC3040945
PMID: 20676043

Abstract

Erlotinib Hydrochloride Receptor, ErbB-3 - metabolism Adenocarcinoma - pathology ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Pancreatic Neoplasms - metabolism Humans Pancreatic Neoplasms - pathology Gene Expression Regulation, Neoplastic Receptor, ErbB-3 - genetics Reverse Transcriptase Polymerase Chain Reaction Adenocarcinoma - drug therapy Blotting, Western Pancreatic Neoplasms - drug therapy Xenograft Model Antitumor Assays Adenocarcinoma - metabolism Animals Signal Transduction - drug effects Tumor Burden - drug effects Cell Line, Tumor Cell Proliferation - drug effects Mice Protein Kinase Inhibitors - pharmacology Quinazolines - pharmacology
url
https://doi.org/10.4161/cbt.10.6.12997View
Published (Version of record) Open

Metrics

10 Record Views
2 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.119 Breast Cancer Scanning
1.119.259 HER2
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details